Bio-Thera closed 2024 with another biosimilar partnership, after signing multiple deals throughout the year in markets across the globe.
This time, the Chinese firm shook hands with Tabuk Pharmaceuticals for its BAT2206 proposed rival to Janssen’s Stelara (ustekinumab), handing over exclusive rights to